

## SUBJECT INDEX

### A

A42867, 285  
Abidjan  
AIDS/HIV-1 infection in, 570  
Acaricides  
nikkomycins as, 279  
Acetate  
*Campylobacter pylori*  
metabolism and, 251  
*Acholeplasma laidlawii*  
plasmid DNAs isolated from,  
91-93  
restriction and modification  
systems in, 88  
Tn916-containing transfor-  
mants of, 95  
transfection of  
electroporation and, 86  
PEG-mediated, 84-85  
*Acholeplasma* species  
genome size of, 83  
Acid phosphatase  
*Campylobacter pylori* and,  
262  
*Leishmania* virulence and,  
513  
Acid secretion inhibitor  
*Campylobacter pylori*, 254  
*Acinetobacter calcoaceticus*  
PQQ synthesis in, 40  
*recA* gene of, 374  
Acquired immunodeficiency syn-  
drome (AIDS)  
epidemiology and modes of  
transmission of  
geographic differences in,  
562-71  
global epidemiology of, 555-  
74  
human herpesvirus type 6  
and, 60  
monitoring of, 559-61  
beginnings of, 557-58  
constraints on, 561-62  
origins of, 556-57  
prevention and control of,  
573  
projections for, 572-73  
*Acremonium lolii*  
peramine from, 280  
Acridine orange stain  
*Campylobacter pylori* and,  
255

*Actinomyces fulvoviridis* var.  
*acarboxicidicus*  
forphenicine from, 402-3  
*Actinomycetes*  
antibiotic production by, 398-  
99  
genetic manipulation of,  
239  
*recA* gene of, 377  
secondary metabolism in,  
408-9  
sporulation in, 414  
*Actinomycetina* D  
coronaviruses and, 308  
*Actinoplanes* species  
BAY e 4609 from, 281  
*Actinoplanes utahensis*  
ciliogargin and, 283  
*Actinorhodin*, 414  
*Actinoxanthin*  
anticancer activity of, 400  
*Aculeacin A*  
*Candida albicans* and, 283  
*Adenosine-pyrimidine nucleoside*  
transport  
*Leishmania* plasma membrane  
and, 515  
Adherence factors  
*Campylobacter pylori*, 253  
Adhesins, 467  
Adriamycin  
human leukemia ML-1 cells  
and, 276  
*Aeromonas caviae*  
*recA* gene of, 374  
A-factor, 405, 414  
Aflatoxins, 416  
biological activities of, 400  
Africa  
AIDS/HIV-1 infection in,  
567-70  
AIDS surveillance in, 560-61  
African trypanosomes  
gene rearrangements in, 452  
Agglutinogens  
pertussis prophylaxis and, 11  
Agriculture  
microbial products for, 278-  
80  
*Agrobacterium rhizogenes*  
agrocin from, 399  
*Agrobacterium* sp. strain ATCC  
21400  
 $\beta$ -glucosidases of, 230  
*Agrobacterium tumefaciens*  
*recA* gene of, 373  
Agrocin  
biological activity of, 399  
AIDS  
See Acquired im-  
munodeficiency syn-  
drome  
Alanine  
*Campylobacter pylori*  
metabolism and, 251  
 $\beta$ -L-Alanine  
spore germination and, 535  
Alcohols  
spore germination and, 536-  
37  
Alkaline phosphatase  
*Campylobacter pylori* and,  
251, 262  
Alkaline protease  
*Pseudomonas aeruginosa* and,  
336, 338  
Allomones, 405  
Allosamidin  
insect chitinase and, 279  
Alphaherpesviruses, 60  
*Amanita muscaria*  
toxicity of, 401  
*Amanita* species  
cyclic peptides from  
RNA polymerase inhibition  
and, 400  
 $\alpha$ -Amanitin  
coronaviruses and, 308  
poxviruses and, 182-83  
Arimocimacin-A  
antiinflammatory activity of,  
402  
Aminopeptidase B  
bestatin and, 273  
secondary metabolites and,  
404  
Aminopeptidases  
*Campylobacter pylori* and,  
251  
4-Aminoquinoline  
*Plasmodium falciparum* and,  
434  
8-Aminoquinolone  
*Plasmodium falciparum* and,  
434  
Amphotericin  
glycosylation in eukaryotic  
cells and, 399

*Anabaena* species  
heterocyst formation in, 702-3

*Anabaena variabilis*  
*recA* gene of, 377-78

*Anaeroplasma* species  
genome size of, 83

*Ansamycins*, 403

*Anthelmymicin*  
nematode/cestode inhibition and, 401

**Anthracyclines**  
anticancer activity of, 400  
biosynthesis of, 405

**Antibiotics**  
rRNA processing and, 122  
secondary metabolites as, 398-99  
See also specific type

**Antibodies**  
immunity to *borreliae* and, 158

**Antigen detection methods**  
*Campylobacter pylori* and, 261

**Antigens**  
*ricketsiial*, 133-34

**Antipain**, 272

**Antiserum**  
bacterial  
requirements for, 10-11  
*Bordetella pertussis*, 11  
*Haemophilus influenzae*, 11  
meningococcus, 10  
type b  
production of, 7-8

**Antitumor agents**  
development of, 276-78

**Aphthoviruses**  
cleavage sequences in, 607  
primary cleavage in, 611-13

**Archaeabacteria**  
rRNA operons of, 107

**Arsenate**  
spore germination and, 537

*Arthrobacter* PI  
RuMP pathway mutants in, 41

*Arthrobacter* species  
genomic DNA probes for, 637

**Arylamidases**  
*Campylobacter pylori* and, 251, 262

*Ascochyta viciae*  
ascofuranone from, 402

*Ascofuranone*  
immunological activity of, 402

**Ascomycetes**  
antibiotics produced by, 398-99

**Ascomycin**  
immunosuppressive activity of, 280

**Asia**  
AIDS/HIV-1 infection in, 570-71

**Aspartate transcarbamoylase**  
(ATCase), 193-214

chimeric, 210-14

*Escherichia coli*  
molecular structure of, 200-3

enzymatic/genetic organizations involving, 195-200

hybrid, 209-10

ornithine transcarbamoylase compared, 207-8

primary sequence of, 203-8

*Aspergillus* marasmins, 404

*Aspergillus alliaceus*  
MY-336a from, 402

*Aspergillus flavus*  
aflatoxins from, 400

*Aspergillus japonicus*  
E-64 isolated from, 275

*Aspergillus* species  
compactin/mevinolin synthesis in, 287  
cyclic peptides from, 283

*Aspergillus terreus*  
lovastatin from, 402  
mustatin from, 275

**Asperlicin**  
cholecytokinin receptor and, 275-76

nontoxic pharmacological activity of, 402

*Asteroleplasma* species  
genome size of, 83

**Australia**  
AIDS/HIV-1 infection in, 571

**Auvercinc**  
toxicity of, 401

**Avermectins**  
agricultural uses of, 279  
GABA receptors and, 285

nematode/cestode inhibition and, 401

**Avian myeloblastosis virus**  
inhibitors of, 281

**Avian spirochetosis**  
etiological agent of, 156

**Avocado sunblotch viroid**  
complementary DNA probes for, 637

**Azide**  
spore germination and, 537

**Azinothrinicin**  
gram-positive activity of, 284

*Aztreonam*, 285

**B**

**Bacilli**  
Koch-Weeks  
classification of, 8-9  
sporulation in, 414-15

*Bacillus brevis*  
tyrocidine synthetase I from gene for, 415

*Bacillus cereus*  
spores of  
germination of, 535

*Bacillus licheniformis*  
β-lactamase production in induction of, 285

*Bacillus megaterium*  
alanine-triggered germination in, 547  
cellulase gene expression in, 224

*Bacillus megaterium* QMB1551  
spore coat of, 534-35  
spores of  
germination of, 535

*Bacillus pumilis*  
amicoumacin-A from, 402

**Bacillus** species  
1-deoxynojirimycin from, 281  
macrolides from, 282

*Bacillus stearothermophilus*  
cellulase gene expression in, 224

*Bacillus subtilis*  
alanine-triggered germination in, 547  
aspartate transcarbamoylase of, 196-97  
cellulase gene expression in, 224  
developmental genes of, 532  
5S RNA of, 118  
germination mutants of, 538-40  
heat-resistant spores of  
formation of, 702  
pyrimidine-arginine biosynthesis in, 195  
*recA* gene of, 376-77  
rRNA operons of, 107-8  
spore coat of  
polypeptides in, 545-46

spores of  
germination of, 535-38  
surfactin from, 406

**Bacteria**  
cell division cycle in  
regulation of, 689-714

coliform  
DNA probes for, 639  
DNA rearrangements in, 452

gram-negative  
bioactive metabolites of, 286  
plasmids isolated from, 91-93

pyrogenicity of, 17

*recA* gene of, 368-76

gram-positive  
*recA* gene of, 376-77

growth at solid-liquid interfaces, 579-97

mercury-resistant colony hybridization and, 633

methanotrophic *Escherichia coli* expressing *Mox* genes from, 37 methane oxidation in, 42 plasmids in, 36 production of chemicals by, 44-48

methylotrophic, 27-52 assimilation genes in, 41-42 auxotrophy markers in, 38 bioremediation and, 51-52 classification of, 28-29 commercial utility of, 43-50 dichloromethane dehalogenase gene of, 42-43 expression of foreign genes in, 37-38 gene cloning vectors and, 31 genetic advances in, 52 genetic analysis and manipulation of, 29-34 gene transfer systems in, 30-31 methanol oxidation genes in, 38-41 molecular biology of, 34-36 mutagenesis in, 33-34 nitrogen fixation genes in, 43 plasmids in, 36 rRNA processing in, 105-24 autoregulation of ribosome content and, 122-24 coregulation with protein synthesis, 121-22 pathways of, 110-16 precursors for, 117-20 rumen genetic manipulation of, 238-39

See also specific type

Bacterial antiserum requirements for, 10-11

Bacterial luciferase, 405

Bacterial spores, 531-48 formation and structure of, 532-35 germination of, 535-38  $\beta$ -L-alanine pathway of, 540-42 alternative pathway of, 542-43 germination genes and, 538-46 models of, 546-48

mutants of reverse genetics and, 545-46 structure of genes involved in, 544-45

Bacterial vaccines requirements for, 11-17

Bacteriophage T4 *recA* gene of, 378

Bacteroidaceae *recA* gene of, 375

*Bacteroides fragilis* *recA* gene of, 375

*Bacteroides nodosus* pilins of, 453-54

*Bacteroides species* DNA probes detecting, 636 genomic DNA probes for, 637

Bafilomycins nematode/cestode inhibition and, 401

Barley yellow dwarf virus complementary DNA probes for, 637

Basidiomycetes antibiotics produced by, 398-99

BAY e 4609 enzyme inhibition by, 281

B-cell differentiation DNA rearrangements in, 452

*Beauveria bassiana* muscardine disease in silk-worms and, 400-1

Belgium AIDS/HIV-1 infection in, 567

Benanomycins HIV and, 280

Benzodiazepines avermectin binding to GABA receptors and, 285

Bestatin activities of, 272-73 anticancer, 400 immunological, 403

Betahepesviruses, 60

B-factor, 405

Bialaphos agricultural use of, 279 herbicidal activity of, 403

Bioactive microbial products See Biopharmaceutins

Biological products regulation of, 9-17 sterility testing of, 17-18

Biopharmaceutins, 271-90 agricultural products, 278-80 cellular proliferation inhibitors, 276-78 cyclic peptides, 283-84 enzyme inhibitors, 274-75 future trends in, 289-90 history of, 272-73

immunomodulators, 273-74 macrolides, 282-83 receptor antagonists, 275-76 screening assays for, 284-85

Bioremediation methylophils and, 51-52

Biosynthetic enzymes uniqueness of, 406-7

Blasticidin S, 280

Bleomycins anticancer activity of, 400

Blood coagulation factors vaccinia gene product and, 179

Blood products AIDS/HIV-1 infection and, 563

*Bordetella pertussis* exotoxin of, 14 *vir* gene of reading-frame shift in, 459

See also Pertussis

*Bordetella pertussis* antiserum, 11

*Bordetella species* taxonomy of, 8-9

*Borrelia burgdorferi* linear plasmids of, 163-64 terminal sequences of, 166 Lyme disease due to, 156

*Borrelia duttonii* linear plasmids of, 163-64 tick-borne relapsing fever due to, 156

*Borrelia hermsii* tick-borne relapsing fever due to, 156

*Borrelia hermsii* antigenic shifts in, 159-60 plasmid copy number and, 169 generation time of, 157-58 gene rearrangements in, 452 linear plasmids of, 163-64 recombination events in, 167 serotypes of, 160 variable antigens of, 161

*Borrelia parkeri* tick-borne relapsing fever due to, 156 variable antigens of, 161

*Borrelia recurrentis* epidemic relapsing fever due to, 156

*Borrelia species*, 155-70 antigenic variation in, 161-62 DNA rearrangements and, 162-63 linear plasmids of, 163-64 recombination between, 164-68

*Borrelia turicatae* tick-borne relapsing fever due to, 156

variable antigens of, 161  
*Bovine coronavirus (BCV)*, 304  
*Bovine viral diarrhea virus (BVDV)*  
 flaviviruses and, 679  
**Brazil**  
 AIDS/HIV-1 infection in, 565-66  
**Breast feeding**  
 HIV-1 transmission and, 568-69  
**Brefeldin A**  
 intracellular processing of antigens and, 274  
**Brevibacterium lactofermentum**  
 cellulase gene expression in, 224  
**Brome mosaic virus**  
 RNA recombination in low-frequency, 326  
**Butyrivibrio fibrisolvens**  
 genetic manipulation of, 238-39  
**Butyrivibrio fibrisolvens EG**  
 xylanase:CMCase activity in, 226  
**Butyrolactones**, 405  
**C**  
*Caldocellum saccharolyticum*  
 $\beta$ -glucosidases of, 230  
**Calphostins**  
 cancer treatment and, 277  
**Calvin-Benson cycle**  
 methylotroph classification and, 28  
*Campylobacter jejuni*  
 cell wall of, 250  
 nonculturable stage of, 9  
*Campylobacter pylori*, 249-63  
 bacteriology of, 250-55  
 diagnosis of, 255-61  
 antigen detection methods and, 261  
 gastric biopsy and, 255-59  
 nucleic acid hybridization and, 261  
 serology and, 259-60  
 urea breath test and, 260-61  
 identification of, 261-63  
 cellular fatty acid analysis and, 262  
 enzyme profiling and, 262  
 protein electrophoresis and, 263  
 restriction endonuclease DNA analysis and, 263  
 metabolism and physiology of, 250-53  
 morphological characteristics of, 250  
 potential virulence factors for, 253-55  
**Canada**  
 AIDS/HIV-1 infection in, 564  
**Cancer**  
 calphostins and, 277  
 human herpesvirus type 6 and, 60  
*Pseudomonas aeruginosa* and, 336  
*Candida albicans*  
 compounds effective against, 283  
*Candida parapsilosis*  
 L-671,329 and, 283  
**Carbamoyl phosphate**  
 pyrimidine-arginine biosynthesis and, 194-95  
**Carbapenems**, 285, 290  
**Carbohydrates**  
*Campylobacter pylori* and, 251  
**Carbol-fuchsin stain**  
*Campylobacter pylori* and, 255  
**Carbon dioxide**  
*Rickettsia prowazekii* multiplication and, 143-44  
**Cardioviruses**  
 cleavage sequences in, 607  
 primary cleavage in, 611-13  
**Caribbean**  
 AIDS/HIV-1 infection in, 564-65  
**Casein kinases**  
 varicella-zoster virus glycoproteins and, 72-74  
**Castanospermine**  
 varicella-zoster glycoprotein gp11 and, 65-69  
**Catalase**  
*Campylobacter pylori* and, 251  
**Cathepsin B**  
 inhibition of, 275  
**Cathepsins**  
 secondary metabolites and, 404  
*Caulobacter crescentus*, 689-714  
*cdc* genes of  
 developmental regulation and, 710-13  
 functional organization of, 696-97  
*cdc* mutations in, 710-11  
 cell division asymmetric, 691  
 chemotactic proteins of, 709-10  
 chromosome replication in, 692-93  
 chromosome segregation in, 693-94  
 developmental events of sequence of, 694  
 flagellar proteins of, 708-9  
 flagellum biosynthesis in, 698-702  
 genetic approaches to, 694-95  
 genetic mapping of, 697-98  
 heat-shock proteins of, 710  
 life cycle of, 691-94  
 mutational analysis of, 695-96  
 pilus assembly in, 698  
 pseudoreversion analysis and, 711-13  
 spatial localization in, 708-10  
 transcription in  
 promoter specificity and, 703-8  
 regulatory proteins and, 707-8  
**Cell differentiation**  
 in bacteria, 689-714  
**Cell-mediated immunity**  
 bestatin and, 273  
**Cellulohydrolases**  
 cellulose degradation and, 220  
**Cellular fatty acid analysis**  
*Campylobacter pylori* and, 262  
**Cellular proliferation**  
 inhibitors of  
 development of, 276-78  
**Cellulase genes**  
 expression in foreign hosts, 224-25  
 expression in native hosts, 222-24  
 multiplicity and organization of, 221-22  
**Cellulases**  
 molecular biology of, 219-40  
 structure and function of, 225-37  
**Cellulolytic organisms**  
 genetic manipulation of, 237-40  
**Cellulose**  
 degradation of  
 molecular biology of, 219-40  
*Cellvibrio mixtus*  
 $\beta$ -glucosidase gene of, 222  
**Cephalosporins**  
 leukocyte elastase and, 287  
*Cephalosporium acremonium*  
 cephalosporin from, 407  
*Cephalosporium caeruleum*  
 cerulenin from, 287  
 Cephalexin, 408  
**Cerulenin**  
 fatty acid synthase and, 287-88  
**Cestodes**  
 antibiotics inhibiting, 401  
**C-factor**, 405

Charcoal  
*Campylobacter pylori* growth and, 250

Chemotactic proteins of *Caulobacter crescentus*, 709-10

Chickenpox varicella-zoster virus and, 60-61

China AIDS/HIV-1 infection in, 571

Chitin synthesis inhibition of microbial products for, 278

*Chlamydia* species rRNA operons of, 109

Chloramphenicol rRNA processing and, 122

Chloramphenicol acetyl transferase (CAT) pilin variation and, 462 in *vaccinia* virions, 187

4-Chlorobiphenyl-degrading organisms isolation of colony hybridization and, 633

*Chloroflexus aurantiacus* cyanobacterial mat sulfide uptake by, 590

Chloroplast glutamine synthetase phosphinothricin and, 279

Cholecystokinin (CCK) antagonist development of, 275-76

Cholera vaccine, 15-16

Cholesterol synthesis inhibitors of, 274, 402

Chymotatin, 272

Chymotrypsin secondary metabolites and, 404

Chytrids terpenoid sex factors of, 413

Ciliogungin antifungal activity of, 283

Circumsporozoite protein, 489

Citrates *Campylobacter pylori* metabolism and, 251

Citrinin cholesterol synthesis and, 402

Citrus exocortis viroid complementary DNA probes for, 637

*Cladosporium cladosporioides* calphostins from, 277

*Claviceps fusiformis* ergot alkaloids from, 407

*Clostridium acetobutylicum* genetic manipulation of, 239

*Clostridium perfringens* genetic manipulation of, 239

*Clostridium thermocellum* cellulase complex of, 221 cellulase-/hemicellulase-encoding genes of, 221 lichenase gene of, 222

*Clostridium thermocellum* EGC xylanase:CMCase activity in, 226

*Clostridium thermocellum* EGD active site of, 236-37

*Clostridium thermocellum* EGE xylanase:CMCase activity in, 226

*Clostridium thermocellum* EGH xylanase:CMCase activity in, 226

*Clostridium thermohydrosulfuricum* genetic manipulation of, 239

Cocaine injection AIDS/HIV-1 infection and, 563

Coliform bacteria DNA probes for, 639

Colony hybridization, 630-34

Compactin cholesterol synthesis and, 274, 280, 402 HMG-CoA reductase and, 278 microbial synthesis of, 287

Complement type b antiserum and, 7

Complement cascade inhibition of, 275

Complement fixation *Campylobacter pylori* and, 259

Complement receptors *Leishmania* and, 502

Complementaria complement cascade and, 275

Computer-enhanced light microscopy sessile microorganisms and, 581-84

Congenital varicella syndrome, 61

Congressional Biologics Control Act (1902), 9

Conjugation gene transfer in methylotrophs and, 30

Conjunctiva *Haemophilus aegyptius* infection of, 9

Conjunctivitis epidemic acute, 8, 20

Cordycepin vaccinia virus and, 177-78

Coronaviruses, 303-27

*Clostridium perfringens* gene assignments in, 306-7 genome structure of, 306-7

genomic RNA replication in, 320-22

mRNAs of transcription of, 309-18

replication of pathway of, 307-9

RNA recombination in high-frequency, 324-26

RNA synthesis in enzymology of, 322-24

negative-stranded, 318-19

virions of structure of, 304-6

*Coxiella* species growth of, 132

Cryptococcal meningitis, 560-61

Cuba AIDS/HIV-1 infection in, 565

Culture *Campylobacter pylori* and, 255-56 *Plasmodium falciparum* and, 493-94

Cyanide spore germination and, 537

Cyanobacteria *recA* gene of, 377-78

Cyclic AMP phosphodiesterase inhibition of, 404

Cyclic peptides biological activities of, 283-84

RNA polymerase inhibition and, 400

Cycloheximide *vaccinia* virus and, 178

Cycloopenin, 405 structural relationship to diazepam, 286-87

Cyclophilin cyclosporin A and, 273

Cyclosporin A immunomodulation and, 273 protein kinase C activity and, 277

Cyclosporins immunological activity of, 402

Cysteine proteinases *Leishmania* virulence and, 515-16

Cystic fibrosis *Pseudomonas aeruginosa* and, 336

Cytocalasin B internalization of *Rickettsia prowazekii* and, 136

Cytchalasins biological activities of, 400

Cytotoxin *Campylobacter pylori*, 254

**D**

Dengue hemorrhagic fever (DHF), 651

Dengue shock syndrome (DSS), 651

Dental caries mutastein for, 275

Deoxymannojirimycin varicella-zoster glycoprotein gplII and, 66-69

1-Deoxyojirimycin enzyme inhibition by, 281-82

Deoxyribonuclease *Campylobacter pylori* and, 251

Destomycin nematode/cestode inhibition and, 401

Destruins, 284, 286 insecticidal activity of, 401

*Desulfurococcus mobilis* rRNA operons of, 107

Diabetes mellitus *Pseudomonas aeruginosa* and, 336

Diazepam cyclopenten structurally related to, 286-87

Dibromomethane methane oxidation mutants in methylotrophs and, 33

Dichloromethane methane oxidation mutants in methylotrophs and, 33

*Dictyostelia* amoeboid aggregation in cyclic AMP and, 413

Dihydrogranolathridin, 289

Dihydromederrhodin A, 289

Dihydroorotate pyrimidine biosynthesis and, 195

*Diphilus ligatus* bioactive metabolites of antimicrobial activity of, 289

Direct urease test *Campylobacter pylori* and, 257-58

Disease germ theory of, 1

DNA-damage repair RecA protein and, 366-67

DNA hybridization most-probable-number, 640-41 See also Nucleic acid hybridization

DNA probe filter hybridization, 628

DNA probes double-stranded, 636-37 nonradioactive, 629-30

radioactive, 629 single-stranded, 637

DNA sequencing *recA* gene and, 379-80

DNA synthesis poxviruses and, 175-79

*Doratomyces* species compactin/mevinolin synthesis in, 287

Doxorubicin HIV and, 281

**E**

E-64, 275

Echinocandin B *Candida albicans* and, 283

Ectoenzymes *Leishmania* virulence and, 509-15

*Ehrlichia* species growth of, 132

EIS See Electrochemical impedance spectroscopy

Elaiophylin antihelminthic activity of, 281

Elastase *Pseudomonas aeruginosa* and, 336, 338 secondary metabolites and, 404

Elastatinal, 272

Electrochemical impedance spectroscopy (EIS) microbial influenced corrosion and, 595-96

Electron microscopy sessile microorganisms and, 593

Electroporation gene transfer in methylotrophs and, 31 mycoplasmas and, 86

ELISA See Enzyme-linked immunosorbent assay

Elsamycin antitumor activity of, 282

Encephalitis Japanese, 651

Endo-alpha-N-acetylgalactosaminidase (O-glycanase) varicella-zoster glycoprotein gplII and, 66-68

Endo-beta-N-acetylglucosaminidase F (Endo F) varicella-zoster glycoprotein gplII and, 66

Endo-beta-N-acetylglucosaminidase H (Endo H)

varicella-zoster glycoprotein gpl and, 64

varicella-zoster glycoprotein gplII and, 67

Endoglycanases cellulose degradation and, 220

*Endothia parasitica* endothiapepsin from, 287

Endothiapepsin renin inhibition and, 287

Enkastins, 275

Enterobacteriaceae *recA* gene of, 368-71

*Enterococcus faecalis* conjugal transposon Tn916 of transfer of, 87

Enteroviruses cleavage sequences in, 607 primary cleavage in, 610-11

Environmental analysis nucleic acid hybridization and, 638-40

Enzyme inhibitors development of, 274-75

Enzyme-linked immunosorbent assay (ELISA) *Campylobacter pylori* and, 259

HIV-1 antibodies and, 556-57

Enzyme profiling *Campylobacter pylori* and, 262

Enzymes biosynthetic uniqueness of, 406-7 methylotrophic production of, 49

Eosin stain *Campylobacter pylori* and, 255

Epidermal growth factor (EGF) pendamycin and, 277 vaccinia gene product and, 179

Epidermal growth factor (EGF) kinase lovendustin and, 278

Epithenamycin E, 285

Erbstatin tyrosine kinase and, 278

Ergot alkaloids, 396, 407, 417 pharmacological effects of, 401

Ergotine, 396

*Erwinia carotovora* *recA* gene of, 370-71

*Erwinia chrysanthemi* genetic manipulation of, 238 *recA* gene of, 370-71

*Erwinia herbicola* aspartate transcarbamoylase of, 204

Erythema potency assay, 16

*Escherichia coli*

- aspartate transcarbamoylase of molecular structure of, 200-3
- auxotrophic mutants of complementation of, 38 complementation with DNA from methanol utilizers, 36
- cellulase gene expression in, 224
- DNA probes for, 636, 639
- flagellum formation in, 700
- pyrimidine-arginine biosynthetic is in, 194-95
- recA* gene of, 368-79
- DNA sequencing of, 379-80
- RecA* protein of, 366-68
- protein sequencing of, 380-83
- rRNA operons of, 106-9
- rRNA processing in pathways of, 110-16
- virulence factors in oligonucleotide probes for, 638

Esterases

- short-chain fatty acid *Campylobacter pylori* and, 251, 262

Eubacteria

- rRNA operons of, 107

Eukaryotes

- DNA rearrangements in, 452
- Eukaryotic cells

  - recA* analogues in, 378-79

- Eupenicillium* species compactin/mevinolin synthesis in, 287

Europe

- AIDS/HIV-1 infection in, 566-67
- Exoenzyme S, 336-37
- Exotoxin A

  - See *Pseudomonas aeruginosa* exotoxin A

F

- Fasac acid, 403
- Fatty acid synthase cerulenin and, 287-88
- Feline infectious peritonitis virus (FIPV), 304
- Fibrobacter succinogenes* EG3 xylanase:CMCase activity in, 226
- Fibronectin receptor (FnR) *Leishmania* and, 502

*Fischerella* species halalinodolinone from, 289

FK-156 immunological activity of, 403

FK-506, 273-74, 280 immunological activity of, 282, 403

Flagellar proteins of *Caulobacter crescentus*, 708-9

Flaviviruses, 649-80

- classification of, 650-51
- conserved RNA sequences and structures of, 673-75
- as disease agents, 651-52
- genetic divergence among, 677-79
- genomic RNA of organization and translation of, 653-55
- life cycle in nature, 650-51
- nonstructural proteins of, 667-71
- replication in cultured cells, 652-53
- RNA replication in, 675-77
- structural proteins of, 660-67
- viral polyprotein of proteolytic processing of, 655-60
- virions of structure and assembly of, 667-71

Flow cytometry

- varicella-zoster virus glycoproteins and, 76-77

Fluorouridylyl

- Campylobacter pylori* and, 259

5-Fluorouracil bone marrow damage due to reversal of, 273

FMDV

- See Foot-and-mouth disease virus

Folate transport

- Leishmania* plasma membrane and, 514

Foot-and-mouth disease virus (FMDV), 604

- leader-catalyzed cleavage in, 616

Formate

- Campylobacter pylori* metabolism and, 251

Forphenicaine anticancer activity of, 400 immunological activity of, 402-3

Forphenicinol immunological activity of, 403

FR-900156, 273

FR-900483 immunological activity of, 403

FR-900490, 273

FR-900494 immunological activity of, 403

FR-900520, 280

FR-900523, 280

FR-901235, 273

Fumarate

- Campylobacter pylori* metabolism and, 251

Fusaric acid, 417

*Fusarium oxysporum* fusaric acid from, 403

*Fusarium* species zearalenone from, 402

G

Galbonolides antifungal activity of, 282

Gammaherpesviruses, 60

Gas-liquid chromatography

- Campylobacter pylori* and, 262

Gastric biopsy

- Campylobacter pylori* and, 255-59

Gastric disease

- Campylobacter pylori* and, 249-50

Gastric mucin protease

- Campylobacter pylori*, 254

Gastric ulcer

- pathogenesis of
- Campylobacter pylori* urease and, 252

Gastric urea

- Campylobacter pylori* and, 258-59

Gastritis

- Campylobacter pylori* and, 250

Gastrointestinal ulcerative disease

- Campylobacter pylori* and, 250

Geldanamycin

- antitumor activity of, 278
- c-myc* oncogene and, 282

GEMS

- See Genetically engineered microorganisms

Gene cloning vectors

- methylotrophs and, 31

Gene probes

- development of, 635-38
- organisms detected by, 631-32

Genetically engineered microorganisms (GEMS), 626

Genetic mapping  
*Caulobacter crescentus* and, 697-98

Gene transfer systems  
 methylotrophs and, 30-31

Genistein, 284

*Gibberella fujikuroi*  
 gibberellic acid from, 403

Gibberellic acid, 403

Gibberellins, 416

Giemsa stain  
*Campylobacter pylori* and, 255

Gimenez stain  
*Campylobacter pylori* and, 255

Gliobactins  
 antifungal activity of, 283-84

*Gloecapsa alpicola*  
*recA* gene of, 377

Glucose transport  
*Leishmania* plasma membrane and, 514

Glucosidases  
 inhibition of, 404

$\alpha$ -Glucosidases  
 microbial inhibitors of, 281-82

$\beta$ -Glucosidases  
 cellulose degradation and, 220

Glutamate  
 PQQ biosynthesis and, 40

$\gamma$ -Glutamyl aminopeptidase  
*Campylobacter pylori* and, 262

Glycine  
*Campylobacter pylori*  
 metabolism and, 251

Glycoproteins  
 varicella-zoster virus, 59-78  
 biosynthesis of, 62-71  
 intracellular trafficking of, 75-77  
 phosphorylation of, 71-75

Gonococci  
 DNA uptake in  
 pilin and, 466  
 nonpilulated phases of, 468-69  
 opacity protein of  
 antigenic variation in, 470  
 pilin antigenic variation in, 469-70  
 pilin genes of  
 interspecies exchange of, 464-65  
 tissue and cell tropisms of, 467-68  
 uptake and chromosomal incorporation of DNA in, 461-62

Gossypol, 417

Gram-negative bacteria  
 bioactive metabolites of, 286  
 plasmids isolated from, 91-93  
 pyrogenicity of, 17  
*recA* gene of, 368-76

Gram-positive bacteria  
*recA* gene of, 376-77

Gram stain  
*Campylobacter pylori* and, 255

Granulocyte elastase  
 human lung tissue damage due to, 286

Guinea pig skin potency assay, 16

*Gymnoascus* species  
 compactin/mevinolin synthesis in, 287

**H**

*Haemophilus aegyptius*, 8-9

*Haemophilus influenzae*  
 capsule of, 6-7  
 influenza and, 5-7  
 isolation of  
 precipitin test for, 10  
 LPS variation in, 459  
 non-type-specific  
 pathogenicity of, 6-7  
*recA* gene of, 375-76  
 type b antiserum of  
 production of, 7-8

*Haemophilus influenzae* anti-serum, 11

*Haemophilus* species  
 DNA uptake sequence of, 466  
 taxonomy of, 8-9

Haiti  
 AIDS/HIV-1 infection in, 565

Haloalkanes  
 microbial degradation of, 51

Halolenes  
 microbial degradation of, 51

*Halobacterium cutirubrum*  
 rRNA operons of, 107, 109

*Hansenula polymorpha*  
 as host for heterologous protein production, 49

Halopinolindolone  
 vasopressin and, 289

Heart disease  
*Pseudomonas aeruginosa* and, 336

Heat-shock proteins  
 of *Caulobacter crescentus*, 710

*Leishmania* virulence and, 516-17

Heat-shock response  
*Leishmania* and, 505-6

*Helicobacter pylori*  
 See *Campylobacter pylori*

*Helminthosporium victoriae*  
 victorin from, 403

Hemagglutination  
*Campylobacter pylori* and, 259

Hematoxylin stain  
*Campylobacter pylori* and, 255

Hemin  
*Campylobacter pylori* growth and, 250

Hemolysis  
*Campylobacter pylori*, 254-55

Hemophilia  
 AIDS/HIV-1 infection and, 563

Hepatitis-A viruses  
 cleavage sequences in, 607  
 DNA probes for, 639

Herbicides  
 phytotoxicity of, 403

Herbimycin A  
*c-myc* oncogene and, 282

Herbimycins  
 antibiotic activity of, 403

Heroin injection  
 AIDS/HIV-1 infection and, 563

Herpesviruses  
 classification of, 60-61

Heterosexual contact  
 AIDS/HIV-1 infection and, 563-64

Hexadecanoic acid  
*Campylobacter pylori* and, 262

Histologic staining  
*Campylobacter pylori* and, 255

HIV  
 See Human immunodeficiency virus

HIV-1  
 See Human immunodeficiency virus-1

HIV-2  
 See Human immunodeficiency virus-2

Hog cholera virus (HCV)  
 flaviviruses and, 679

Homolanasine  
 insecticidal/herbicidal activity of, 403

Homologous recombination  
 RecA protein and, 366

Homosexual contact  
 AIDS/HIV-1 infection and, 562-63

Human coronavirus (HCV), 304

Human immunodeficiency virus (HIV)  
 benanomicins and, 280

Human immunodeficiency virus (HIV) reverse transcriptase doxorubicin and, 281 screen for, 285 streptonigrin and, 281

Human immunodeficiency virus-1 (HIV-1) origins of, 556-57

Human immunodeficiency virus-1 (HIV-1) infection epidemiology and modes of transmission of geographic differences in, 562-71 global epidemiology of, 555-74 monitoring of, 558-59 constraints on, 561-62 prevention and control of, 573 projections for, 572-73

Human immunodeficiency virus-2 (HIV-2), 571-72

3-Hydroxy-3-methyl glutaryl CoA (HMG-CoA) reductase inhibitors of, 274

3-Hydroxy-3-methyl glutaryl CoA (HMG-CoA) synthase mevalonate pathway and, 274

3-Hydroxy-octadecanoic acid *Campylobacter pylori* and, 262

Hygromycin nematode/cestode inhibition and, 401

*Hyphomicrobium X* expression of foreign genes in, 37

Hypochlorhydria *Campylobacter pylori* and, 254

Hypoglycemia pertussis encephalopathy and, 20

*Hypomyces* species compactin/mevinolin synthesis in, 287

**I**

Ibotenic acid toxicity of, 401

IC201 immunological activity of, 402

Immune function bestatin and, 273

Immune response *Pseudomonas aeruginosa* and, 336

Immune sera boarrial infections and, 158

Immunity cell-mediated bestatin and, 273

Immunoblot *Campylobacter pylori* and, 259

Immunodeficiency *Pseudomonas aeruginosa* and, 336

Immunofluorescence *Campylobacter pylori* and, 255

Immunomodulators development of, 273-74

Immunoperoxidase test *Campylobacter pylori* and, 255

Imperfect fungi antibiotics produced by, 398

India AIDS/HIV-1 infection in, 571

Infectious bronchitis virus (IBV), 304

Influenza *Haemophilus influenzae* and, 5-7 1918-19 epidemic, 4-5

Insects secondary metabolites and, 400-1

Interleukins bestatin and, 273

Intestinal maltase microbial inhibitors of, 281

Intestinal sucrase microbial inhibitors of, 281

Intracellular parasitism *Leishmania* virulence and, 501-6

Intravenous drug abuse AIDS/HIV-1 infection and, 563

Iron exotoxin A transcription and, 341-44

Italy AIDS/HIV-1 infection in, 567

Ivermectin agricultural use of, 279

**J**

Japanese encephalitis, 651

Jietacins antifungal activity of, 401

**K**

K-76 complement cascade and, 275

Kaposi's sarcoma, 556, 558, 560-61

Kenya AIDS/HIV-1 infection in, 569-70

$\alpha$ -Ketoglutarate *Campylobacter pylori* metabolism and, 251

*Kitasatosporia kifunense* FR-900494 from, 403

*Kitasatosporia papulosa* carbapenem from, 285

*Klebsiella oxytoca* growth rate on granular activated carbon, 592

*Klebsiella pneumoniae* human lung infection by granulocyte elastase and, 286

Koch-Weeks bacillus classification of, 8-9

Kojic acid, 416

Kyasanur Forest disease, 651

**L**

L-156373, 276

L-364718, 276

L-671329, 283

Lactate *Campylobacter pylori* metabolism and, 251

Lactivincin structure of, 276

*Lactobacillus plantarum* cellulase gene expression in, 224-25

*Lactobacillus* species genomic DNA probes for, 637

*Legionella pneumophila* *recA* gene of, 376

*Leishmania major* metacyclogenesis in, 505 proteolytic activity of gp63 in, 510-13

Leishmaniasis, 500

*Leishmania* species differentiation of, 504-6 intracellular survival of, 506 parasite, vector, animal models for, 500-1 receptor-mediated endocytosis of, 502-4

*Leishmania* virulence, 499-522 cysteine proteinases and megasomes and, 515-16 heat-shock proteins and, 516-17 intracellular parasitism and, 501-6 regulation of, 517-19

surface glycoproteins-ectoenzymes and, 509-15  
 surface lipophosphoglycan and, 507-9

Leucine aminopeptidase  
 bestatin and, 273  
*Campylobacter pylori* and, 262  
 secondary metabolites and, 404

Leukemia  
 P338  
 glioblasts and, 284  
*Pseudomonas aeruginosa* and, 336

Leukocyte elastase  
 cephalosporins and, 287

Leupeptins, 272

Light microscopy  
 sessile microorganisms and, 580-84

Lincomycin  
 aerial mycelium formation and, 288

Lipids  
 sessile microorganisms and, 584-85

Lipophosphoglycan  
*Leishmania* virulence and, 507-9

lipopolysaccharide (LPS)  
 bacterial biomass on surfaces and, 586-87  
 typhus group rickettsiae and, 134-35

*Listeria* species  
 gene probes for, 637  
 virulence factors in  
 oligonucleotide probes for, 638

LL-F28249  
 parasitoidal activity of, 282

*Lotus* rhizobia  
 DNA probes detecting, 636

Lovastatin  
 cholesterol synthesis and, 274, 402

Lovastatin  
 epidermal growth factor kinase and, 278

Loxistatin  
 muscular dystrophy and, 275

LPS  
 See Lipopolysaccharide

Luciferase  
 bacterial, 405

Lyme disease  
 etiological agent of, 156

Lysine  
*Campylobacter pylori*  
 metabolism and, 251

**M**

Macrolides  
 biological activities of, 282-83  
 insecticidal activity of, 401

Macromycin  
 anticancer activity of, 400

Macrophages  
*Leishmania* binding to, 502-4  
 leishmanial infection of, 520

Macrotetrolides  
 insecticidal activity of, 401

Malaria, 2

Malaria parasites  
 chromosomal deletions in, 485-86  
 chromosomal polymorphism in, 483-86  
 chromosome of, 481-83  
 environmental pressure and, 493-95

gametocytes of  
 cytoskeleton and microtubular organization of, 441  
 nucleus, chromosomes, DNA content of, 442-43  
 origin of, 431  
 ribosomes of, 441-42

gene duplication in, 486-87  
 genetic diversity in, 479-95  
 genetic recombination in, 483-85

life cycle of, 430, 481  
 point mutations and selection in, 491-93  
 reduction division of, 483  
 sex determination in, 437  
 sexual differentiation in, 429-45

sexual stages of  
 as specialized cells, 440-45  
 transformation in mosquito vector, 438-40

sexual stage-specific protein expression in, 443-45

surface antigen genes of  
 repetitive sequences in, 487-91

Malate  
*Campylobacter pylori*  
 metabolism and, 251

Mannose-fucose receptors (MFR)  
*Leishmania* and, 502

Mannose-N-acetylglucosamine receptor  
*Leishmania* and, 502

*Matarizium anisopliae*  
 destruxins from, 284

Mederhodins, 289

Megasomes  
*Leishmania* virulence and, 515-16

Meningitis  
 cryptococcal, 560-61

Meningococci  
 interspecies exchange and, 465  
 nonpiliated phases of, 468-69  
 opacity protein of  
 antigenic variation in, 470

Opa proteins of, 455  
 pilin antigenic variation in, 469-70

tissue and cell tropisms of, 467-68

uptake and chromosomal incorporation of DNA in, 461

Meningococcus antiserum, 10

Mepacrine  
*Plasmodium falciparum* and, 434

Mercury-resistant bacteria  
 isolation of  
 colony hybridization and, 633

Metacyclogenesis, 504-5

Metal corrosion  
 sessile microorganisms and, 595-96

Methane monooxygenase  
 oxidation pathway for methanotrophs and, 42

soluble  
 compounds synthesized by, 44-48

Methanol dehydrogenase  
 methanol oxidation in methylo trophs and, 38

Methanotrophs  
*Escherichia coli* expressing  
 Mox genes from, 37  
 methane oxidation in  
 genes for, 42  
 plasmids in, 36  
 production of chemicals by, 44-48

3-Methoxybenzamide  
*Leishmania* differentiation and, 505

6-Methoxy-2-benzoxazolinone, 417

Methyl antranilate  
 spore germination and, 537

Methylene octadecanoic acid  
*Campylobacter pylori* and, 262

*Methyllobacillus flagellatum*  
 auxotrophic markers of, 88  
 auxotrophic mutants complemented with DNA from, 36

auxotrophic mutants of, 33  
foreign promoters functional in, 37-38  
*recA* gene homologs cloned from, 34-35  
RuMP pathway mutants in, 41  
*Methyllobacterium extorquens*  
    AM1  
    assimilation genes in, 41-42  
    *Escherichia coli* expressing  
        *Mox* genes from, 37  
        growth on dichloromethane, 43  
    marker exchange in, 34  
    methanol oxidation mutants in, 33  
    *moxF* gene of  
        promoter region for, 35  
    *Mox* genes of, 39-40  
    PQQ synthesis in, 41  
    pRK404 subcloning vector in  
        instability of, 31  
    Tn5 delivery vehicle for, 34  
*Methyllobacterium organophilum*  
    XX  
    assimilation genes in, 41  
    gene transfer system in, 30  
    growth on dichloromethane, 43  
    methanol oxidation mutants in, 33  
    *moxF* gene of  
        promoter region for, 35  
    *Mox* genes of, 39-40  
*Methyllobacterium* species  
    codon usage in, 35  
    *dcmA* gene of  
        translational start site for, 35  
    *moxF* gene of  
        expression in *Escherichia coli*, 37  
*Methyllobacterium* sp. DM4  
    dichloromethane utilization in, 42-43  
*Methylococcus capsulatus*  
    gene transfer system in, 30  
    *moxF* genes cloned from, 39  
*Methylenomonadaceae*  
    *recA* gene of, 375  
*Methylenomonas albus* BG8  
    methane oxidation mutants in, 33  
    *moxF* gene of  
        translational start site for, 35  
*Methylenomonas clara*  
    cryptic plasmid of  
        promoter region from, 35  
*Methylphilus methylotrophus*  
    auxotrophic mutants complemented with DNA from, 36  
expression of foreign genes  
    in, 37-38  
marker exchange in, 34  
plasmid transfer in, 34  
*recA* gene of, 375  
transposon mutagenesis in, 33-34  
*Methylphilus methylotrophus*  
    AS1  
    growth yield of  
        recombinant DNA technology and, 49  
*Methylosinus* species  
    marker exchange in, 34  
*Methylosinus trichosporium*  
    OB3b  
    methane oxidation mutants in, 33  
    *moxF* genes cloned from, 39  
*Methylotroph* genes  
    expression in foreign hosts, 36-37  
*Methylotrophs*, 27-52  
    assimilation genes in, 41-42  
    auxotrophy markers in, 38  
    bioremediation and, 51-52  
    classification of, 28-29  
    commercial utility of, 43-50  
    dichloromethane dehalogenase gene of, 42-43  
    expression of foreign genes in, 37-38  
    gene cloning vectors and, 31  
    genetic advances in  
        commercial implications of, 52  
    genetic analysis and manipulation of  
        techniques for, 29-34  
    gene transfer systems in, 30-31  
    methanol oxidation genes in, 38-41  
    molecular biology of, 34-36  
    mutagenesis in, 33-34  
    nitrogen fixation genes in, 43  
    plasmids in, 36  
    6-Methylsalicylic acid  
        *Penicillium patulum* and, 413  
    Mevalonate pathway  
        HMG-CoA synthase and, 274  
    Mevinolin  
        cholesterol synthesis and, 274, 402  
        HMG-CoA reductase and, 278  
        microbial synthesis of, 287  
    Mexico  
        AIDS/HIV-1 infection in, 566  
    Microaerophilism  
        *Campylobacter pylori* and, 253  
Microcalorimetry  
    sessile microorganisms and, 587-88  
*Microcoleus chthonoplastes*  
    cyanobacterial mat  
    photosynthesis transitions in, 590  
Microelectrodes  
    sessile microorganisms and, 588-90  
Microfungi  
    antibiotics produced by, 398-99  
Milbemycins  
    insecticidal activity of, 401  
Mitomycin C  
    bone marrow damage due to reversal of, 273  
Molluscides, 84  
*Molluscum contagiosum* virus  
    benign tumors due to, 179  
Monacolin K, 402  
*Monascus ruber*  
    monacolin K from, 402  
*Monascus* species  
    compactin/mevinolin synthesis in, 287  
Monensin  
    biological activities of, 399  
    varicella-zoster glycoprotein gpl and, 64  
    varicella-zoster glycoprotein gpII and, 66-68  
    varicella-zoster glycoprotein gpIII and, 69  
Monobactams, 285  
Monoclonal antibodies  
    *Campylobacter pylori* and, 255  
*Moraxella bovis*  
    pili of, 453  
Mosquito exflagellation factor (MEF), 440  
Mosquito vector  
    malaria parasites in, 438-40  
Mouse hepatitis virus (MHV), 304  
Mucorales  
    trisporic acid sex hormones of, 413  
Muscular dystrophy  
    loxastatin and, 275  
Mutagenesis  
    *RecA* protein and, 367-68, 384-85  
Mustastatin, 275  
Mutational analysis  
    *Caulobacter crescentus* and, 695-96  
Mutational biosynthesis, 289-90  
MY-336a  
    nontoxic pharmacological activity of, 402

*Mycobacterium avium*  
oligonucleotide probes for, 638

*Mycophenolic acid*, 397

*Mycoplasma capricolum*  
A+T content of, 83

*Mycoplasma flocculare*  
restriction and modification systems in, 88  
transposable elements of, 98

*Mycoplasma gallisepticum*  
PEG-mediated transformation of, 85  
rRNA operons of, 109

*Mycoplasma hominis*  
Tn916-containing transformants of, 95  
Tn916 transferred into, 87

*Mycoplasma hyopneumoniae*  
restriction and modification systems in, 88  
transposable elements of, 98

*Mycoplasma hyorhinis*  
PEG-mediated transformation of, 85  
Tn916-containing transformants of, 95  
transposable elements of, 98

*Mycoplasma mycoides* subsp. *mycoides*  
PEG-mediated transformation of, 85  
plasmid isolated from, 90-91  
restriction and modification systems in, 88  
Tn916-containing transformants of, 95  
transfection of  
electroporation and, 86

*Mycoplasma pneumoniae*  
genetic variation in, 96-98

*Mycoplasma pulmonis*  
genetic variation in, 96-98  
homologous recombination in, 85-86  
PEG-mediated transformation of, 85  
restriction and modification systems in, 88  
Tn916-containing transformants of, 95

*Mycoplasma* species  
genome size of, 83  
rRNA operon organization in, 108-9

Mycoplasmas, 81-99  
extrachromosomal DNAs and, 89-95  
genetic variation in, 95-98  
gene transfer in, 84-88  
phylogenetic relationship of, 82-84  
plasmids isolated from, 89-91

transposable elements of, 93-95

*Mycoplasma viruses*, 89

*Mycotoxins*  
biological activities of, 400

*Myxococcus* species  
fruiting body formation in, 703  
macrolides isolated from, 282

*Myxococcus xanthus*  
fruiting in  
cyclic AMP and, 413

**N**

Nairobi  
AIDS/HIV-1 infection in, 568

Naphthalene degradation gene probe analysis and, 633

*Nectria lucida*  
FR-900483 from, 403

*Neisseria cinerea*  
Opa proteins of, 456

*Neisseriae*  
gene expression in  
slipped strand mispairing and, 456-59  
pathogenic  
gene families in, 453-56  
transformation-mediated recombination and, 463-66

pilin genes of  
regulation of, 466-67  
pilin variation in  
mechanisms of, 459-62  
protein variation in, 451-71

*recA* gene of, 374

*Neisseria flavescens*  
interspecies exchange and, 464

Opa proteins of, 456

*Neisseria gonorrhoeae*  
DNA uptake deficient mutants of, 465

gene rearrangements in, 452

interspecies exchange and, 464-65

Opa proteins of, 455

pilin genes of, 453  
interstrain exchange and, 464  
regulation of, 466-67

*recA* gene of, 374

*Neisseria lactamica*  
Opa proteins of, 455-56

*Neisseria meningitidis*  
interspecies exchange and, 464

Opa proteins of, 456

pilin genes of, 453

Nematodes  
antibiotics inhibiting, 401

Neocarzinostatin  
anticancer activity of, 400

Neosurugatoxin  
shellfish poisoning and, 401

Neuraminidase  
varicella-zoster glycoprotein gpl and, 64  
varicella-zoster glycoprotein gpII and, 67  
varicella-zoster glycoprotein gpIII and, 69

New Zealand  
AIDS/HIV-1 infection in, 571

Nikkomycins  
agricultural uses of, 278-79  
insecticidal activity of, 401

Nitrogen  
*Campylobacter pylori*  
metabolism and, 251-52

Nitrogen fixation  
methylophilic and, 43

*Nocardia mediterranea*  
rifamycin from, 405

Nojirimycin  
glucosidase inhibition and, 404

Nucleic acid hybridization, 625-42

*Campylobacter pylori* and, 261  
detection sensitivity and  
specificity of  
improvements in, 640-41  
environmental applications of, 638-40  
environmental recovery and, 634-35  
gene probe development and, 635-38  
probe labelling and hybrid detection and, 629-30  
probe technology and, 627  
target nucleic acid sources and, 630-34

Nucleoside transport  
*Leishmania* plasma membrane and, 514

Nucleotides  
*Leishmania* virulence and, 513-14

**O**

Oceania  
AIDS/HIV-1 infection in, 571

Octadecanoic acid  
*Campylobacter pylori* and, 262

Octadecenoic acid  
*Campylobacter pylori* and, 262

Oligonucleotide probes, 638

Oligostatins  
enzyme inhibition by, 281

Operons  
rRNA, 106-10  
transcripts of, 110

Organ transplantation  
cyclosporin A and, 273

Ornithine decarboxylase  
inhibition of, 404

Ornithine transcarbamoylase  
(OTCase)  
aspartate transcarbamoylase  
compared, 207-8  
primary sequence of, 203-8

Oxidase  
*Campylobacter pylori* and,  
251

Oxytocin  
inhibitors of  
development of, 276

**P**

*Paecilomyces carneus*  
immunomodulator from,  
273

*Paecilomyces* species  
compactin/mevinolin synthesis  
in, 287

Pamamycin  
aerial mycelium formation  
and, 414  
antibacterial activity of, 288

Pamaquine  
*Plasmodium falciparum* and,  
434

Pancreatic  $\alpha$ -amylase  
microbial inhibitors of, 281

Papain  
inhibition of, 275  
secondary metabolites and,  
404

*Paracoccus denitrificans*  
closed circular plasmid DNA  
transformation in, 30  
codon usage in, 35  
methanol oxidation mutants  
in, 33  
*mxoF* gene of  
expression in *Escherichia coli*, 37  
translational start site for,  
35  
plasmid transfer in, 34

Paraherquamide  
antihelminthic use of, 279

Parasitism  
intracellular  
*Leishmania* virulence and,  
501-6

Patulin  
isolation of, 400

Paxisterol  
analgesic activity of, 285,  
402

Pendolmycin  
epidermal growth factor and,  
277

*Penicillium brevicompactum*  
compactin from, 402

*Penicillium chartesi*  
paraherquamide from, 279

*Penicillium citrinum*  
compactin from, 402

*Penicillium cyclopium*  
cyclopenin-viridinactin synthesis  
in, 405

*Penicillium paraherquei*  
paraherquamide from, 279

*Penicillium patulin*  
patulin from, 400

*Penicillium patulum*  
hyphal differentiation in  
6-methylsalicylic acid and,  
413

*Penicillium* species  
compactin/mevinolin synthesis  
in, 287

macrolides isolated from, 282

*Penicillium stoloniferum*  
mycophenolic acid from, 397

Pepsin  
secondary metabolites and,  
404

Peptidase inhibitors  
identification of, 272

Peptidoglycan  
bacterial biomass on surfaces  
and, 586  
rickettsial, 135

Peramine  
agricultural use of, 280

Periodeate-thiocarbohydrazide sil-  
ver proteinate  
varicella-zoster virus gly-  
coproteins and, 75

Pertussis  
antisera therapy for, 11  
Pertussis encephalopathy  
hypoglycemia and, 20

Pertussis toxin  
pertussis antisera/pertussis  
immune globulin and, 11  
whooping cough and, 14, 20

Pertussis vaccine  
potency assay for, 12  
standardization of, 12-15

Pestiviruses  
flaviviruses and, 679

Phagocytes  
cytotoxic  
bestatin and, 273

Phase contrast microscopy  
*Campylobacter pylori* and,  
255

Phaseotoxin, 403

Phenicin  
cholesterol synthesis and,  
274

Phenoxazinone synthase  
production of, 290

*Phoma* species  
compactin/mevinolin synthesis  
in, 287

Phosphatidyl inositol  
microbial inhibitors of, 277

Phosphinotrichin  
chloroplast glutamine syn-  
thetase and, 279  
plant glutamine synthetase  
and, 403

Phosphinotrichinyl-alanyl-alanine  
See Bialaphos

Phosphoamidase  
*Campylobacter pylori* and,  
262

Phospholipase C  
*Pseudomonas aeruginosa* and,  
336

Phospholipids  
sessile microorganisms and,  
584-85

Phosphoramidon, 275

Phycomyctes  
antibiotics produced by,  
399

*Pichia pastoris*  
host-vector system based on,  
49

Picornaviral polyproteins  
maturation cleavage in, 616-  
18  
primary cleavage events in,  
609-13  
proteolytic processing of,  
603-19  
secondary cleavage events in,  
613-16

Picornaviruses  
family of, 603-9  
genetic relationship among,  
605  
genomic RNAs of, 605-7  
RNA recombination in  
low-frequency, 326  
viral proteins of, 607-9

*Pithomyces charitarum*  
mycotoxins produced by,  
400

Plant pathogens  
toxic secondary metabolites  
of, 403-4

Plaque hybridization, 630-34

Plasma  
pyrogenicity of, 17

Plasmids  
gram-negative bacterial, 91-  
93

in methylotrophic bacteria, 36  
mycoplasma, 89-91

*Plasmodium berghei*  
gametocytes of  
nucleus, chromosomes,  
DNA content of, 443  
ribosomes of, 442  
sexual differentiation in, 433  
sexual stage-specific protein  
expression in, 444  
spontaneous exflagellation of,  
439

*Plasmodium chabaudi*  
gametocytes of  
production of, 435  
ribosomes of, 442

*Plasmodium elongatum*  
gametogenesis in, 440

*Plasmodium falciparum*  
chromosomal deletions in,  
485-86  
chromosomal polymorphism  
in, 483-86  
chromosome of, 481-83  
environmental pressure and,  
493-95  
gametocytes of  
cytoskeleton and microtubu-  
lar organization of,  
441  
nucleus, chromosomes,  
DNA content of, 442-  
43  
ribosomes of, 441-42  
gene duplication in, 486-87  
genetic diversity in, 479-95  
genetic recombination in,  
483-85  
life cycle of, 430, 481  
point mutations and selection  
in, 491-93  
reduction division of, 483  
sexual differentiation in, 432-  
33  
sexual stage-specific protein  
expression in, 443-44  
surface antigen genes of  
repetitive sequences in,  
487-91

*Plasmodium gallinaceum*  
gametocytes of  
origin of, 431  
sexual stage-specific protein  
expression in, 444  
spontaneous exflagellation of,  
438-40

*Plasmodium knowlesi*  
immune pressure and, 494-95

*Plasmodium malariae*  
sexual differentiation in, 431

*Plasmodium vivax*  
gametocytes of  
origin of, 431  
sexual differentiation in, 431

sexual stage-specific protein  
expression in, 444  
gametocytes of  
origin of, 431  
sexual differentiation in, 433

*Plasmodium yoelii*  
gametocytes of  
origin of, 431

*Plasmodium telfairiae*  
bioactive metabolites of  
insecticidal activity of, 289

Plum pox virus  
complementary DNA probes  
for, 637

Pneumococcus  
S and R colonial forms of, 4

*Pneumocystis carinii* pneumonia,  
556, 557

Poisoning  
shellfish  
etiological agents for, 401

Poliiovirus, 604

Polyacrylamide gel elec-  
trophoresis  
*Campylobacter pylori* and,  
263

*Polygonium brachysporum*  
glidobactins from, 283

Polyclonal antisera  
*Campylobacter pylori* and,  
255

Polymerase chain reaction  
(PCR)  
target DNA sequences and,  
641

Polyoxins  
agricultural uses of, 278-79

Polysoomes  
rRNA maturation in, 120-24

Porothramycin  
biological activities of, 287

Potato spindle tuber viroid  
complementary DNA probes  
for, 637

DNA probes for, 639

Poxviruses  
cellular/viral transcriptases  
and, 181-83

DNA synthesis of host cells  
and, 175-79

envelope of, 178

intracellular replication and  
expression of, 174-75

pathogenesis of, 179-81

reciprocity interactions of,  
173-88

replication of  
nucleocytoplasmic interac-  
tions during, 183-88

PQQ  
biosynthesis of, 40

Precipitin test  
*Haemophilus influenzae* and,  
10-11

Proguanil  
*Plasmodium falciparum* and,  
434

Prokaryotes  
pyrimidine-arginine biosynthe-  
sis in, 194-95  
rRNA genes in, 106-9

Proline-4-hydroxylase  
inhibition of, 404

Proline transport  
*Leishmania* plasma membrane  
and, 514

Prosorugatoxin  
shellfish poisoning and, 401

Protein electrophoresis  
*Campylobacter pylori* and,  
263

Protein kinase C  
adriamycin and, 276  
inhibitors of  
screen for, 285  
sangivamycin and, 280  
staurosporine and, 277

Protein kinases  
varicella-zoster virus gly-  
coproteins and, 72-74

Proteins  
methylo trophic production of,  
49-50

Protein sequencing  
RecA protein and, 380-83

*Proteus mirabilis*  
recA gene of, 368-69

*Proteus vulgaris*  
aspartate transcarbamoylase  
of, 204  
recA gene of, 369

Pseudobactins, 405, 412

Pseudomonadaceae  
recA gene of, 371-73

*Pseudomonas aeruginosa*  
auxotrophic mutants of  
complementation of, 38  
complementation with DNA  
from methanol utiliz-  
ers, 36-37  
colony hybridization and,  
640  
ornithine transcarbamoylase  
genes of, 207  
PAK pilus, 469-70  
pilins of, 453-54  
pilus assembly in, 698  
recA gene of, 371-72  
regulatory genes in, 338-41  
resistance in biofilm to tobra-  
mycin, 591  
surface-active agent of, 406

*Pseudomonas aeruginosa* ex-  
oenzyme S, 336-37

*Pseudomonas aeruginosa* ex-  
otoxin A, 335-58  
crystallographic analysis of,  
350-51

domains of  
functional analysis of, 351-  
57

enzymatic activity of  
expression of, 350  
molecular analysis of, 57  
production of  
environmental factors in,  
337-38  
regulation of, 337-49  
promoters of  
regulation of, 344-47  
secretion of, 349  
synthesis of  
genes involved in, 338-41  
transcription of  
regulation of, 341-44

*Pseudomonas fluorescens*  
light microscopy and, 581-82

*Pseudomonas phaseolicola*  
phaseotoxin of, 403

*Pseudomonas putida*  
*recA* gene of, 372-73

*Pseudomonas* species  
aspartate transcarbamoylases  
of, 199

*Pseudomonas syringae*  
*recA* gene of, 372-73

*Pseudomonas tabacum*  
wildfire toxin of, 403

Pseudoreversion analysis  
*Caulobacter crescentus* and,  
711-13

Puerto Rico  
AIDS/HIV-1 infection in, 565

Pyochelin  
*Pseudomonas aeruginosa* and,  
338

Pyocyanine  
isolation of, 397

Pyoverdin  
*Pseudomonas aeruginosa* and,  
338

Pyrimethamine  
*Plasmodium falciparum* and,  
434, 493-94

Pyrimidine-arginine biosynthesis  
physiological organization of,  
194-95

*Pythium ultimum*  
citrinin from, 402

**Q**

Quantitative electron microscop-  
ic autoradiography  
varicella-zoster virus gly-  
coproteins and, 75-76

Quellung test  
*Haemophilus influenzae* and,  
11

Quinine  
*Plasmodium falciparum* and,  
434

**R**

Rabbit coronavirus (RCV), 304

*recA* gene  
of actinomycetes, 377  
of bacterial viruses, 378  
of cyanobacteria, 377-78  
eukaryotic analogues of, 378-79  
of gram-negative bacteria,  
368-76  
of gram-positive bacteria,  
376-77  
interactions dependent on  
conservation of, 383-85  
phylogenetic distribution of,  
368-79  
structural conservation of,  
379-83

RecA protein  
activities of, 366-68  
DNA-damage repair and, 366-67  
general recombination and,  
366  
gene regulation and, 367  
mutagenesis and, 367-68,  
384-85  
structural conservation of,  
379-83

Receptor antagonists  
development of, 275-76

Recombinant DNA technology  
bioactive microbial products  
and, 272  
growth yield of *Methylophilus*  
*methylotrophus* AS1 and,  
49  
macrolide synthesis and, 283  
methylotrophs and, 28  
target enzyme production and,  
284-85

Recombination  
homologous  
*RecA* protein and, 366

Relapsing fever, 153-70  
etiological agents of, 156  
immunology of, 156-60

Renin  
endothiapepsin and, 287  
secondary metabolites and,  
404

Restriction endonuclease DNA  
analysis  
*Campylobacter pylori* and,  
263

Reticulol  
cyclic AMP phosphodiesterase  
and, 404

Rhamnolipid  
*Pseudomonas aeruginosa* and,  
336

Rhinoviruses  
cleavage sequences in, 607  
primary cleavage in, 610-11

*Rhizobiaceae*  
*recA* gene of, 373

*Rhizobium*  
*Rhizobium japonicum*  
*recA* gene of, 373  
rhizobiotoxin of, 403

*Rhizobium leguminosarum*  
*recA* gene of, 373

*Rhizobium meliloti*  
*recA* gene of, 373

*Rhizobium* species  
DNA probes detecting, 636

Ribose transport  
*Leishmania* plasma membrane  
and, 514

Ribosomal RNA processing  
See rRNA processing

Ribulose monophosphate path-  
way  
methylotroph classification  
and, 28

*Rickettsia akari*  
rickettsial pox due to, 132

*Rickettsia conorii*  
spotted fever due to, 132

*Rickettsial* pox  
etiological agent of, 132

*Rickettsia prowazekii*  
epidemic typhus due to, 132  
growth kinetics of, 138-39  
internalization by host cells,  
136-38  
membrane transport systems  
of, 140-42

metabolism of, 143  
multiplication of  
carbon dioxide and, 143-44  
protein 1 of, 133  
serotype protein antigens of,  
134

*Rickettsia rickettsii*  
slime layer of, 132-33  
spotted fever due to, 132

endothelial injury due to,  
144-45

*Rickettsia* species, 131-47  
growth of, 139-40  
host entry and exit of, 136-39  
intracellular damage due to,  
144-45  
metabolism of, 142-44  
molecular genetics of, 145-47  
morphology and composition  
of, 132-35  
transport of, 140-42

*Rickettsia tsutsugamushi*  
growth kinetics of, 138-39  
penetration into mouse lym-  
phoblasts, 136  
peptidoglycan deficiency in,  
135

scrub typhus due to, 132  
surface antigens of, 134-35

*Rickettsia typhi*  
endemic typhus due to, 132  
growth kinetics of, 138-39  
protein 1 of, 133  
serotype protein antigens of, 134

Rifamycin, 405

RNA polymerase  
coronavirus RNA replication and, 322-24  
inhibition of  
cyclic peptides and, 400

RNA probes  
single-stranded, 637

RNase D  
RNA processing and, 113

RNase E  
RNA processing and, 113

RNase III  
rRNA processing and, 112-13

RNase M5  
RNA processing and, 113

RNase P  
RNA processing and, 113

*Rochalimaea* species  
growth of, 132

Romania  
AIDS/HIV-1 infection in, 567

rRNA  
5S  
maturation of, 116  
16S  
maturation of, 114-16  
23S  
maturation of, 113-14

rRNA genes  
in prokaryotes, 106-9  
rRNA operons, 106-10  
transcripts of, 110

rRNA processing, 105-24  
autoregulation of ribosome content and, 122-24  
coregulation with protein synthesis, 121-22  
pathways of, 110-16  
precursors for, 117-20

Rubella virus  
flaviviruses and, 679

Rumen bacteria  
genetic manipulation of, 238-39

*Ruminococcus albus*  
endoglucanase-encoding genes of, 221-22  
genetic manipulation of, 238-39

*Ruminococcus flavefaciens* FD-1  
cellA gene of  
celloextrinase encoded by, 224

S

*Saccharomyces cerevisiae*  
cellulase gene expression in, 224-25  
peptide mating factors of, 413  
pyrimidine-arginine biosynthesis in, 195  
pyrimidine nucleotide biosynthesis in, 199  
RecA protein of, 379

*Salmonella* species  
DNA probes detecting, 636

*Salmonella typhi*  
isolation of  
precipitin test for, 10

*Salmonella typhimurium*  
aspartate transcarbamoylase of, 203  
flagellin mutations in, 709  
flagellin promoter in, 460  
flagellum formation in, 700  
recA gene of, 371

Sangivamycin  
kinase inhibition and, 404  
protein kinase C and, 280

S antigen, 489-91

Sarkomycin, 404

SCH36605  
antiinflammatory activity of, 280

Schick Test, 16

*Schizophyllum commune* EGL active site of, 236

*Sclerotinia fructicola*  
arthospore formation in, 405

Scrub typhus  
etiological agent of, 132

Secondary metabolism  
regulation of, 407-8

Secondary metabolites, 395-419  
activity in animals, 399-403  
activity in plants, 403-4  
antibiotic activity of, 398-99  
as autoregulators, 404-5  
as enzyme inhibitors, 404  
as mineral scavengers, 405  
pigmented, 406  
structural complexity of, 406-9  
as surfactants, 405-6

Serine pathway  
methylotroph classification and, 28

Serology  
*Campylobacter pylori* and, 259-60

Serotype protein antigens (SPAs)  
rickettsial, 133-34

*Serratia marcescens*  
aspartate transcarbamoylase of, 204, 209-10

recA gene of, 369-70

Serum  
*Campylobacter pylori* growth and, 250

Serum proteinase inhibitors (SERPINS)  
poxviruses and, 180-81

Sessile microorganisms, 579-97  
behavior of, 580-84  
biofilm sampling of, 591  
biomass of  
determination of, 584-87  
metabolic activity of  
determination of, 587-96  
metal corrosion and, 595-96  
nutrient utilization by, 591-95

Setamycin  
anti-trichomonad and -nematode activity of, 282  
nematode/cestode inhibition and, 401

Shellfish poisoning  
etiological agents for, 401

*Shigella flexneri*  
recA gene of, 370

Shingles  
varicella-zoster virus and, 60-61

Shope fibroma virus  
benign tumors due to, 179  
DNA synthesis of host cells and, 176

Sialoadenitis virus (SDAV), 304

Simian immunodeficiency virus (SIV), 571

Single cell protein (SCP)  
methylotrophic production of, 49

SIV  
See Simian immunodeficiency virus

Smallpox, 3

*Sorangium* species  
macrolides isolated from, 282

Soviet Union  
AIDS/HIV-1 infection in, 567

Spain  
AIDS/HIV-1 infection in, 567

Spirochetes  
relapsing fever due to, 155-70

*Spiroplasma citri*  
restriction and modification systems in, 88  
transfection of  
electroporation and, 86

*Spiroplasma* species  
genome size of, 83  
plasmids isolated from, 89-90

Spores  
See Bacterial spores

Sporidesmins  
hepatotoxicity of, 400

Sporopollenin, 411  
 Spotted fever  
     etiological agents of, 132  
*Stachybotrys complementi*  
     K-76 produced by, 275  
*Staphylococcus aureus*  
     human lung infection by  
     granulocyte elastase and,  
     286  
     Tn4001 isolated from, 95  
*Staphylococcus* species  
     methicillin-resistant  
     aztreonam and, 284  
 Starch  
     *Campylobacter pylori* growth  
     and, 250  
 Staurosporine  
     bleb formation in K562 cells  
     and, 285  
     protein kinase C and, 277  
*Streptococcus faecus*  
     plasmid pVA380-1 isolated  
     from, 91  
*Streptococcus mutans*  
     dental plaque and, 275  
*Streptococcus pneumoniae*  
     human lung infection by  
     granulocyte elastase and,  
     286  
*Streptomutin* A, 289  
*Streptomyces actiosides*  
     staurosporine from, 277  
*Streptomyces alboniger*  
     autoregulators in, 414  
     pamamycin from, 288  
*Streptomyces albus*  
     enkephalinase inhibitors from,  
     275  
*Streptomyces aureofaciens*  
     vasodilator compounds from,  
     402  
*Streptomyces avermitilis*  
     avermectins from, 401  
*Streptomyces cinnamonensis*  
     monensin from, 399  
*Streptomyces cirratus*  
     IC201 from, 402  
*Streptomyces coelicolor*  
     sporulation in, 414  
*Streptomyces dimorphogenes*  
     nov. sp.  
     trestatins from, 281  
*Streptomyces fradiae*  
     recA gene of, 377  
*Streptomyces fulvoviridis*  
     carbapenems from, 290  
*Streptomyces gabonae*  
     MY-336a from, 402  
*Streptomyces galilaeus*  
     homoloanidine from, 403  
*Streptomyces griseus*  
     butyrolactones from, 405  
     sporulation in, 414  
*Streptomyces hygroscopicus*  
     autoregulation of, 404-5  
     bialaphos from, 279, 403  
     herbimycins from, 403  
     macrolides from, 273-74  
*Streptomyces hygroscopicus subsp. limoneus*  
     valiomine from, 281  
*Streptomyces lavendulae*  
     complestatin from, 275  
*Streptomyces lividans*  
     cellulase gene expression in,  
     224  
     genetic manipulation of,  
     239  
     phenoxazinone synthase in  
     gene for, 290  
*Streptomyces myxogenes*  
     oligostatins from, 281  
*Streptomyces olivaceorubescens*  
     FK-156 from, 403  
     immunostimulating peptide  
     from, 273  
*Streptomyces olivoreticuli*  
     bestatin from, 273  
*Streptomyces sagonensis*  
     herbicides from, 403  
*Streptomyces* species  
     macrolides from, 282  
*Streptomyces stauroporae*  
     staurosporine from, 277  
*Streptomyces tsukubaensis*  
     FK-506 from, 403  
     macrolides from, 273-74  
*Streptomyces violaceus*  
     FK-156 from, 403  
     immunostimulating peptide  
     from, 273  
*Streptomyces virginiae*  
     virginiamycin from, 405  
*Streptomyces viridochromogenes*  
     bialaphos from, 403  
     butyrolactones from, 405  
*Streptomycin*, 411  
*Streptonigrin*  
     HIV and, 281  
*Streptovitacin A*  
     vaccinia virus and, 178  
*Succinate*  
     *Campylobacter pylori*  
     metabolism and, 251  
*Sulfadiazine*  
     *Plasmodium falciparum* and,  
     434  
*Surface glycoproteins*  
     *Leishmania* virulence and,  
     509-15  
*Surface tubule elements (STEs)*  
     poxviruses and, 177  
*Surfactants*  
     bacterial, 405-6  
*Surfactin*, 406  
 Swainsonine  
     varicella-zoster glycoprotein  
     gpII and, 65-69  
 T  
 Tanzania  
     AIDS/HIV-1 infection in, 569  
 T-cell differentiation  
     DNA rearrangements in, 452  
 Teleocidin B, 277  
 TEM  
     See Transmission electron  
     microscopy  
 Tetradecanoic acid  
     *Campylobacter pylori* and,  
     262  
 Tetrazolium plate test  
     spore germination and, 538  
 Thailand  
     AIDS/HIV-1 infection in,  
     570-71  
*Thermomonosporus fusca*  
     cellulase synthesis in, 223-24  
*Thermoproteus tenax*  
     rRNA operons of, 109  
*Thermothrix thiopara*  
     growth rate of, 581  
*Thermus thermophilus*  
     rRNA operons of, 107, 109  
*Thiobacillus ferrooxidans*  
     genomic DNA probes for,  
     637  
     recA gene of, 375  
 Tobacco mosaic virus (TMV)  
     herbimycin A and, 403  
 Tobramycin  
     *Pseudomonas aeruginosa* re-  
     sistance to, 591  
 Togaviruses  
     flaviviruses and, 679  
*Tolyphocladium* species  
     cyclosporins from, 402  
 Tooth decay  
     See Dental caries  
 Transforming growth factor- $\alpha$   
     (TGF- $\alpha$ )  
     vaccinia gene product and,  
     179  
 Transmissible gastroenteritis  
     virus (TGEV), 304  
 Transmission electron micros-  
     copy (TEM)  
     sessile microorganisms and,  
     593  
 Transpeptidase  
     *Campylobacter pylori* and,  
     262  
 Transposon mutagenesis  
     methylophilic and, 33-34  
 Trestatins  
     enzyme inhibition by, 281  
 Trichloroethylene

microbial degradation of, 51-52

*Trichoderma reesei*  
cellulase genes of, 222  
genetic manipulation of, 237-38

*Trichoderma reesei* CBHI  
Woodward's reagent K and, 236

*Trichoderma* species  
compactin/mevinolin synthesis in, 287

Trypsin  
secondary metabolites and, 404

Tunicamycin  
varicella-zoster glycoprotein gpl and, 64  
varicella-zoster glycoprotein gplI and, 68

Turkey coronavirus (TCV), 304

Typhoid fever, 2

Typhoid vaccine, 15

Typhus  
etiological agents of, 132

Tyrosidine synthetase I, 415

Tyrosine  
PQQ biosynthesis and, 40

Tyrosine kinase  
erbstatin and, 278  
staurosporine and, 277

**U**

Ubenimex, 273  
immunological activity of, 403

Undecylprodigiosin, 414

United States  
AIDS/HIV-1 infection in, 562-64  
AIDS surveillance in, 559-60

Urea  
gastric  
*Campylobacter pylori* and, 258-59

Urea breath test  
*Campylobacter pylori* and, 260-61

*Ureaplasma* species  
genome size of, 83

*Ureaplasma urealyticum*  
restriction and modification systems in, 88

Urease  
*Campylobacter pylori*, 251-52, 254

*Ustilago maydis*  
RecA protein of, 378-79

**V**

Vaccines  
bacterial

requirements for, 11-17  
cholera, 15-16  
pertussis  
potency assay for, 12  
standardization of, 12-15  
typhoid, 15

Vaccinia gene product, 179-80

Vaccinia virus  
glycolipid metabolism and, 178  
malignant tumors due to, 179

Valiomine  
enzyme inhibition by, 281

Vancomycin  
peptidoglycan precursor and, 285

Varicella-zoster glycoprotein gpl, 62-65

Varicella-zoster glycoprotein gplI, 65-69

Varicella-zoster glycoprotein gpIII, 69-70

Varicella-zoster glycoprotein gpIV, 70-71

Varicella-zoster glycoprotein gpV, 71

Varicella-zoster virus  
clinical diseases due to, 60-61  
virion and genome of, 61

Varicella-zoster virus glycoproteins, 59-78  
biosynthesis of, 62-71  
intracellular trafficking of, 75-77  
phosphorylation of, 71-75

Vasopressin  
hapolinodolinone and, 289

Verlamelin, 284

*Verticillium lamellicola*  
verlamelin from, 284

*Vibrio anguillarum*  
recA gene of, 373

*Vibrio cholerae*  
El Tor strains of, 16  
nonculturable stage of, 9  
pili of, 453  
recA gene of, 373-74

*Vibrio fischeri*  
luciferase from, 405

Vibrionaceae  
recA gene of, 373-74

Victorin, 403

Vimentin  
exotoxin A and, 337

Vincomycin A  
antitumor activity of, 404

Virginiamicin, 405

cholecystokinin receptor and, 281

Viridictin, 405

Virions  
coronavirus  
structure of, 304-6

Viroids

DNA probes detecting, 636

Viruses

DNA rearrangements in, 452

mycoplasma, 89

**W**

Warthin-Starry silver stain  
*Campylobacter pylori* and, 255

Water molds  
terpenoid sex factors of, 413

Whooping cough  
pertussis toxin and, 14, 20

Wildfire toxin, 403

Woodward's reagent K  
*Trichoderma reesei* CBHI and, 236

Wound infection  
*Pseudomonas aeruginosa* and, 336

WS-1228A  
vasodilator activity of, 402

WS-1228B  
vasodilator activity of, 402

**X**

Xenotonic products, 288

X potato virus  
complementary DNA probes for, 637

**Y**

Yaba monkey virus  
benign tumors due to, 179

Yeast  
antibiotics produced by, 399

Yellow fever, 650-51

*Yersinia pestis*  
recA gene of, 371  
yopA gene of  
reading-frame shift in, 459

*Yersinia* species  
gene probes for, 637  
virulence factors in  
oligonucleotide probes for, 638

**Z**

Zaire  
AIDS/HIV-1 infection in, 569

*Zalherion arboricola*  
L-671329 from, 283

Zearentone  
agricultural uses of, 402

Zn-proteinase  
*Leishmania* virulence and, 509-13

*Zymomonas mobilis*  
cellulase gene expression in, 224-25

